{
    "xml": "<topic id=\"PHP2313\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/olanzapine-embonate\" basename=\"olanzapine-embonate\" title=\"OLANZAPINE EMBONATE\">\n<title>OLANZAPINE EMBONATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_366\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/olanzapine\">Olanzapine</xref>\n</p>\n<data name=\"vtmid\">17067211000001109</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_850282295\" title=\"Antipsychotics (second-generation, depot injections)\">Antipsychotics (second-generation, depot injections)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" title=\"ANTIPSYCHOTIC DRUGS\" namespace=\"/drug-classes/antipsychotic-drugs\">ANTIPSYCHOTIC DRUGS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Olanzapine Pamoate</p>\r\n</body>\n<topic id=\"PHP47306\" outputclass=\"indicationsAndDose\" rev=\"1.24\" parent=\"/drugs/olanzapine-embonate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 10&#8239;mg oral olanzapine daily)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;75 years</p>\n<p>Initially 210&#8239;mg every 2&#8239;weeks, alternatively initially 405&#8239;mg every 4&#8239;weeks, then maintenance 150&#8239;mg every 2&#8239;weeks, alternatively maintenance 300&#8239;mg every 4&#8239;weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 15&#8239;mg oral olanzapine daily)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;75 years</p>\n<p>Initially 300&#8239;mg every 2&#8239;weeks, then maintenance 210&#8239;mg every 2&#8239;weeks, alternatively maintenance 405&#8239;mg every 4&#8239;weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 20&#8239;mg oral olanzapine daily)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By deep intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 300&#8239;mg every 2&#8239;weeks, then maintenance 300&#8239;mg every 2&#8239;weeks (max. per dose 300&#8239;mg every 2&#8239;weeks), adjusted according to response, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseAdjustments\">\n<title>Dose adjustments due to interactions</title>\n<sectiondiv>\n<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47347\" outputclass=\"contraindications\" rev=\"1.12\" parent=\"/drugs/olanzapine-embonate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Children</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47373\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/olanzapine-embonate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Bone-marrow depression</ph>; <ph outputclass=\"caution\">diabetes mellitus (risk of exacerbation or ketoacidosis)</ph>; <ph outputclass=\"caution\">hypereosinophilic disorders</ph>; <ph outputclass=\"caution\">low leucocyte count</ph>; <ph outputclass=\"caution\">low neutrophil count</ph>; <ph outputclass=\"caution\">myeloproliferative disease</ph>; <ph outputclass=\"caution\">paralytic ileus</ph>; <ph outputclass=\"caution\">when transferring from oral to depot therapy, the dose by mouth should be reduced gradually</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47262\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/olanzapine-embonate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia</ph>; <ph outputclass=\"sideEffect\">hypercholesterolaemia</ph>; <ph outputclass=\"sideEffect\">hypertriglyceridaemia</ph>; <ph outputclass=\"sideEffect\">increased appetite</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">oedema</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">amnesia</ph>; <ph outputclass=\"sideEffect\">bradycardia</ph>; <ph outputclass=\"sideEffect\">epistaxis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatitis</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">rhabdomyolysis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Erythema</ph>; <ph outputclass=\"sideEffect\">nodules</ph>; <ph outputclass=\"sideEffect\">pain at injection site</ph>; <ph outputclass=\"sideEffect\">swelling</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsOverdosageInformation\">\n<title>Overdose</title>\n<sectiondiv>\n<p>Post-injection reactions have been reported leading to signs and symptoms of overdose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47292\" outputclass=\"pregnancy\" parent=\"/drugs/olanzapine-embonate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use only if potential benefit outweighs risk; neonatal lethargy, tremor, and hypertonia reported when used in third trimester.</p>\n<p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p>\n<p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47385\" outputclass=\"breastFeeding\" parent=\"/drugs/olanzapine-embonate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid&#8212;present in milk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47310\" outputclass=\"hepaticImpairment\" parent=\"/drugs/olanzapine-embonate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Initially 150&#8239;mg every 4 weeks; increase with caution in moderate impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47278\" outputclass=\"renalImpairment\" parent=\"/drugs/olanzapine-embonate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Initially 150&#8239;mg every 4 weeks.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47236\" outputclass=\"monitoringRequirements\" parent=\"/drugs/olanzapine-embonate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Observe patient for at least 3 hours after injection.</p>\n<p>Treatment requires careful monitoring for optimum effect.</p>\n<p>Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.</p>\n<p>Fasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP47407\" outputclass=\"directionsForAdministration\" rev=\"1.9\" parent=\"/drugs/olanzapine-embonate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57877\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.10\" parent=\"/drugs/olanzapine-embonate\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intramuscular</ph> use</p>\n<p>When prescribing, dispensing or administering, check that this is the correct preparation&#8212;this preparation is used for <i>maintenance</i> treatment and should <b>not</b> be used for the rapid control of an <i>acute</i> episode.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP2313-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/olanzapine-embonate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77874\" title=\"Powder and solvent for suspension for injection\" namespace=\"/drugs/olanzapine-embonate/powder-and-solvent-for-suspension-for-injection\">Powder and solvent for suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78155\" namespace=\"/treatment-summaries/psychoses-and-related-disorders\" title=\"Psychoses and related disorders\" count=\"1\" rel=\"backlink\">Psychoses and related disorders</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_366\" namespace=\"/interactions/list-of-drug-interactions/antipsychotics/olanzapine\" title=\"Olanzapine\" count=\"1\" rel=\"link\">Olanzapine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34569\" namespace=\"/drug-classes/antipsychotic-drugs\" title=\"ANTIPSYCHOTIC DRUGS\" count=\"1\" rel=\"link\">ANTIPSYCHOTIC DRUGS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77874\" namespace=\"/drugs/olanzapine-embonate/powder-and-solvent-for-suspension-for-injection\" title=\"Powder and solvent for suspension for injection\" count=\"1\" rel=\"link\">Powder and solvent for suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP2313",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/olanzapine-embonate",
    "basename": "olanzapine-embonate",
    "title": "OLANZAPINE EMBONATE",
    "interactants": [
        {
            "id": "bnf_int_366",
            "label": "Olanzapine"
        }
    ],
    "vtmid": "17067211000001109",
    "drugClassification": [
        "Antipsychotics (second-generation, depot injections)"
    ],
    "inheritsFromClass": [
        "ANTIPSYCHOTIC DRUGS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Olanzapine Pamoate"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 10 mg oral olanzapine daily)",
                        "html": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 10&#8239;mg oral olanzapine daily)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 210 mg every 2 weeks, alternatively initially 405 mg every 4 weeks, then maintenance 150 mg every 2 weeks, alternatively maintenance 300 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.",
                        "html": "<p>Initially 210&#8239;mg every 2&#8239;weeks, alternatively initially 405&#8239;mg every 4&#8239;weeks, then maintenance 150&#8239;mg every 2&#8239;weeks, alternatively maintenance 300&#8239;mg every 4&#8239;weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>",
                        "ageGroup": "18&#8211;75 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 15 mg oral olanzapine daily)",
                        "html": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 15&#8239;mg oral olanzapine daily)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 300 mg every 2 weeks, then maintenance 210 mg every 2 weeks, alternatively maintenance 405 mg every 4 weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.",
                        "html": "<p>Initially 300&#8239;mg every 2&#8239;weeks, then maintenance 210&#8239;mg every 2&#8239;weeks, alternatively maintenance 405&#8239;mg every 4&#8239;weeks, maintenance dose to be started after 2 months of initial treatment, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>",
                        "ageGroup": "18&#8211;75 years"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 20 mg oral olanzapine daily)",
                        "html": "Maintenance in schizophrenia in patients tolerant to olanzapine by mouth (patients taking 20&#8239;mg oral olanzapine daily)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "deep intramuscular injection"
                    ],
                    "textContent": "By deep intramuscular injection",
                    "html": "By deep intramuscular injection"
                },
                "adult": [
                    {
                        "textContent": "Initially 300 mg every 2 weeks, then maintenance 300 mg every 2 weeks (max. per dose 300 mg every 2 weeks), adjusted according to response, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.",
                        "html": "<p>Initially 300&#8239;mg every 2&#8239;weeks, then maintenance 300&#8239;mg every 2&#8239;weeks (max. per dose 300&#8239;mg every 2&#8239;weeks), adjusted according to response, dose to be administered into the gluteal muscle, consult product literature if supplementation with oral olanzapine required.</p>"
                    }
                ]
            }
        ],
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "title": "Dose adjustments due to interactions",
                "textContent": "Dose adjustment may be necessary if smoking started or stopped during treatment.",
                "html": "<p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Children",
                "html": "Children"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Bone-marrow depression",
                "html": "Bone-marrow depression"
            },
            {
                "type": "cautions",
                "textContent": "diabetes mellitus (risk of exacerbation or ketoacidosis)",
                "html": "diabetes mellitus (risk of exacerbation or ketoacidosis)"
            },
            {
                "type": "cautions",
                "textContent": "hypereosinophilic disorders",
                "html": "hypereosinophilic disorders"
            },
            {
                "type": "cautions",
                "textContent": "low leucocyte count",
                "html": "low leucocyte count"
            },
            {
                "type": "cautions",
                "textContent": "low neutrophil count",
                "html": "low neutrophil count"
            },
            {
                "type": "cautions",
                "textContent": "myeloproliferative disease",
                "html": "myeloproliferative disease"
            },
            {
                "type": "cautions",
                "textContent": "paralytic ileus",
                "html": "paralytic ileus"
            },
            {
                "type": "cautions",
                "textContent": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually",
                "html": "when transferring from oral to depot therapy, the dose by mouth should be reduced gradually"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Arthralgia",
                        "html": "Arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypercholesterolaemia",
                        "html": "hypercholesterolaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hypertriglyceridaemia",
                        "html": "hypertriglyceridaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "increased appetite",
                        "html": "increased appetite",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "amnesia",
                        "html": "amnesia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "bradycardia",
                        "html": "bradycardia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "epistaxis",
                        "html": "epistaxis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hepatitis",
                        "html": "Hepatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rhabdomyolysis",
                        "html": "rhabdomyolysis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Erythema",
                        "html": "Erythema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nodules",
                        "html": "nodules",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pain at injection site",
                        "html": "pain at injection site",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "swelling",
                        "html": "swelling",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "textContent": "If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.",
                "html": "<p>If the dose needs to be reduced to alleviate side-effects, it is important to recognise that the plasma-drug concentration may not fall for some time after reducing the dose, therefore it may be a month or longer before side-effects subside.</p>"
            }
        ],
        "overdosageInformation": [
            {
                "type": "overdosageInformation",
                "textContent": "Post-injection reactions have been reported leading to signs and symptoms of overdose.",
                "html": "<p>Post-injection reactions have been reported leading to signs and symptoms of overdose.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use only if potential benefit outweighs risk; neonatal lethargy, tremor, and hypertonia reported when used in third trimester.\n\nExtrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.\n\nFollowing maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.",
                "html": "<p>Use only if potential benefit outweighs risk; neonatal lethargy, tremor, and hypertonia reported when used in third trimester.</p><p>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</p><p>Following maternal use of antipsychotic drugs in the third trimester, neonates should be monitored for symptoms including agitation, hypertonia, hypotonia, tremor, drowsiness, feeding problems, and respiratory distress.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid&#8212;present in milk.",
                "html": "<p>Avoid&#8212;present in milk.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Initially 150 mg every 4 weeks; increase with caution in moderate impairment.",
                "html": "<p>Initially 150&#8239;mg every 4 weeks; increase with caution in moderate impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Initially 150 mg every 4 weeks.",
                "html": "<p>Initially 150&#8239;mg every 4 weeks.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Observe patient for at least 3 hours after injection.\n\nTreatment requires careful monitoring for optimum effect.\n\nBlood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.\n\nFasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.",
                "html": "<p>Observe patient for at least 3 hours after injection.</p><p>Treatment requires careful monitoring for optimum effect.</p><p>Blood lipids and weight should be measured at baseline, at 3 months (weight should be measured at frequent intervals during the first 3 months), and then yearly with antipsychotic drugs. Patients taking olanzapine require more frequent monitoring of these parameters: every 3 months for the first year, then yearly.</p><p>Fasting blood glucose should be measured at baseline, at 4&#8211;6 months, and then yearly. Patients taking olanzapine should have fasting blood glucose tested at baseline, after one months&#8217; treatment, then every 4&#8211;6 months.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.",
                "html": "<p>Correct injection technique (including use of z-track technique) and rotation of injection sites are essential.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "specificity": {
                    "textContent": "With intramuscular use",
                    "html": "With <ph outputclass=\"route\">intramuscular</ph> use",
                    "routes": [
                        "intramuscular"
                    ]
                },
                "textContent": "When prescribing, dispensing or administering, check that this is the correct preparation&#8212;this preparation is used for maintenance treatment and should not be used for the rapid control of an acute episode.",
                "html": "<p>When prescribing, dispensing or administering, check that this is the correct preparation&#8212;this preparation is used for <i>maintenance</i> treatment and should <b>not</b> be used for the rapid control of an <i>acute</i> episode.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77874",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78155",
                "label": "Psychoses and related disorders",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_366",
                "label": "Olanzapine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34569",
                "label": "ANTIPSYCHOTIC DRUGS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77874",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}